{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RISPERDAL+CONSTA&page=2", "query": { "intervention": "RISPERDAL CONSTA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RISPERDAL+CONSTA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T00:01:21.661Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01844700", "title": "1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "High Risk MC4R Genotype", "Low Risk MC4R Genotype", "One Week or Less Antipsychotic Lifetime Exposure" ], "interventions": [ { "name": "Ziprasidone", "type": "DRUG" }, { "name": "aripiprazole, quetiapine, or risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "13 Years to 18 Years" }, "enrollment_count": 14, "start_date": "2013-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 1, "location_summary": "Glen Oaks, New York", "locations": [ { "city": "Glen Oaks", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844700" }, { "nct_id": "NCT00176202", "title": "Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Divalproex Sodium", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "10 Years to 20 Years" }, "enrollment_count": 65, "start_date": "2003-04", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 3, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176202" }, { "nct_id": "NCT02893371", "title": "Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Fluoxetine / Olanzapine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Lurasidone", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Mirtazapine", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Desvenlafaxine", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" }, { "name": "Doxepin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1037352, "start_date": "2016-09", "completion_date": "2019-06-30", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893371" }, { "nct_id": "NCT00515723", "title": "Glucose and Lipid Metabolism on Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Type 2 Diabetes Mellitus", "Hyperglycemia" ], "interventions": [ { "name": "risperidone", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 96, "start_date": "2001-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 2, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00515723" }, { "nct_id": "NCT00423878", "title": "Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 215, "start_date": "2007-01", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 28, "location_summary": "Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more", "locations": [ { "city": "Colton", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423878" }, { "nct_id": "NCT01677377", "title": "Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "RBP-7000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 45, "start_date": "2012-08", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 2, "location_summary": "Little Rock, Alaska • Long Beach, California", "locations": [ { "city": "Little Rock", "state": "Alaska" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677377" }, { "nct_id": "NCT01451736", "title": "Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia (Recent-onset)" ], "interventions": [ { "name": "paliperidone palmitate", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 146, "start_date": "2011-10", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-04-11", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451736" }, { "nct_id": "NCT00796302", "title": "Treatment of Severe Childhood Aggression (The TOSCA Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention Deficit Disorder With Hyperactivity" ], "interventions": [ { "name": "Methylphenidate HCl", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Parent Management Training (PMT)", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Michael Aman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 168, "start_date": "2008-08", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 4, "location_summary": "Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Stony Brook", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796302" }, { "nct_id": "NCT01770600", "title": "Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Impulsivity", "Active Suicidal Ideation", "Depression" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "Riperidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 0, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770600" }, { "nct_id": "NCT01639872", "title": "Clozapine for Cannabis Use in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Cannabis Abuse", "Cannabis Dependence", "Dual Diagnosis" ], "interventions": [ { "name": "Clozapine", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2013-05-01", "completion_date": "2017-03-29", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-09-18T00:01:21.661Z", "location_count": 9, "location_summary": "Garden Grove, California • Oakland, California • Miami, Florida + 6 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01639872" } ] }